Company profile

Zydus Lifesciences

ZYDUSLIFE · NSE

Public Market Listing

ZYDUSLIFENSE

NSE primary exchange listing

Live quotes, historical charts, and market capitalization for Zydus Lifesciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Desidustat(Oxemia)
Approved
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
Ranibizumab(Lucentis)
Approved
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Saroglitazar(Lipaglyn)
Phase 2
PPAR-alpha/PPAR-gammaSmall molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.